Navigation Links
VERICIS Cardiovascular Information System

ProductsVERICIS Cardiovascular Information System
Company Camtronics Medical Systems
Item VERICIS Cardiovascular Information System
Features 
  • Multi-modality study review with the industry leading VERICIS Cardiac Workstation, specifically designed to meet the visualization requirements of todays high resolution diagnostic imaging systems
  • Secure anywhere, anytime access to studies and reports via the Web from standard PCs
  • Comprehensive physician reporting for cardiac cath, echocardiography, pediatric echo, nuclear cardiology, vascular ultrasound and peripheral vascular for faster report turnaround and improved report consistency and completeness
  • ACC-NCDR certified reporting module for simplified participation in the ACCs national quality measurement service
  • Robust tools for administrative and clinical research that simplify statistical reporting, outcomes analysis and identification of best practices across all of your cardiovascular services
  • Integrated hemodynamic monitoring with VERICIS PhysioLog that simplifies monitoring and improves the accuracy and consistency of procedural documentation
  • Built-in inventory management with bar code scanning for quick and accurate capture of equipment usage, simplified re-ordering and precise cost management
  • Bi-directional hospital information system (HIS) interface for reduced entry of patient demographics, automatic pre-fetch of prior studies and automatic distribution of results
  • Connectivity to Radiology PACS allowing for the expanded capability to review a patients associated radiology studies
  • Highly scaleable system architecture to support any number of modality, workstation or hospital connections
  • Flexible image archiving options including DVD-R, AIT, NAS, SAN and enterprise archive to meet a wide range of data storage requirements
  • And with the VERICIS CardioWorks EMR for the cardiology office practice, it is now possible to digitally link your patients inpatient and cardiology office-based records.
    • Description Built on a single information technology platform, the VERICIS Cardiovascular Information System (CVIS) integrates data from different sites (office, clinic, hospital) and different sources (interventional and diagnostic x-ray angiography, echo, nuclear, MR, hemodynamics, reports, HIS) to create a comprehensive digital record on the cardiac patient.

    VERICIS empowers you to:
  • Make better clinical decisions in less time
  • Improve outcomes and quality of care
  • Increase efficiency and reduce costs
  • Provide better service to your internal and external customers

    • The VERICIS CVIS is an information management and workflow solution for the entire cardiovascular service line.
    Info Camtronics Medical Systems
    Customer Service: (800) 634-5151
    Web site: http://www.camtronics.com

    Related medicine products :

    1. VERICIS PhysioLog
    2. ACE Kinetic Hypertension / Cardiac Evaluation, Cardiovascular 001-KK-ACK4 Angiotensin Converting Enzyme
    3. ACE Kinetic Hypertension / Cardiac Evaluation, Cardiovascular 001-KK-ACK Angiotensin Converting Enzyme
    4. ACE Kinetic Hypertension / Cardiac Evaluation, Cardiovascular 001-KK-ACKX Angiotensin Converting Enzyme
    5. ACTH EIA Hypertension / Cardiac Evaluation, Cardiovascular 021-SDX018
    6. Myoglobin EIA Lipid / Protein Quantification, Cardiovascular 024-IDC-13 Muscle Disease
    7. Myoglobin RIA Lipid / Protein Quantification, Cardiovascular 024-IDC-11 Muscle Disease
    8. Angiotensin II RIA Hypertension / Cardiac Evaluation, Cardiovascular 001-RK-A22
    9. Vitamin B6 Jumbo REA Vitamin Assays, Cardiovascular 001-RK-VB6N
    10. Vitamin B6 REA Vitamin Assays, Cardiovascular 001-RK-VB6
    11. Cortisol EIA Hypertension / Cardiac Evaluation, Cardiovascular 012-MDKCO1 Stress Hormones
    Cholesterol/HDL Standard 50 mg/dl.
    Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol
    Ready to use liquid single reagent for automated chemistry analyzers. Linearity to 1000 mmol/L
    Ammonia reagent is used for the quantitative and enzymatic determination of ammonia in human plasma.
    Medicine Products:
    (Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
    (Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
    (Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
    (Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
    Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
    ...Infirmary in Scotland will be the first in United ...eration in recipient. The Health Minister Andy Ker...ld be done followed by ten the next year//. In li...f liver is transplanted and regenerated following ...
    Canadians flocking to India for quick and efficient medical treatment
    ...ab) drug is found to be useful in treating patient...by the European Medicines Agency (EMEA) for use in...rent drugs//. Xolair can be used in the treatment ...ffects of the new drug on long time usage has to b...
    ...suggests that the melanocortin system is an import...l neuronal plasticity observed after chronic morph...is accompanied by the development of morphine tole...s associated with opiate treatment. Possible modul...
    Other Medicine News:Health News:Inhibition of morphine tolerance by spinal melanocortin receptor blockade 2
    (Date:10/7/2008)...., Oct. 7 /- A study published in the...m cell self-renewal,reported that InVitria,s ( ht...an serum albumin) was an effective replacement to ...icle entitled, "The ground state of embryonic stem...ed Cellastim as a recombinant,albumin in place of ...
    (Date:10/7/2008)...Oct. 7 /- Aerovance Inc. today report...se I trial of its Aerovant,inhalation powder that ...local irritancy following asthma patients, inhalat... be the highest of three doses investigated in,Aer...heduled to begin early,next year. Evidence gathere...
    (Date:10/7/2008).../- Ardea Biosciences, Inc.,...itled "RDEA119, a Potent,and Highly Selective MEK1...um (DSS) -- induced Chronic Colitis in Mice," was ...ogy (ACG) 2008 Annual Meeting in Orlando,Florida....l study of,RDEA119, the Company,s lead mitogen-act...
    (Date:10/7/2008)...k, October 7 /-, - 125 Pat...ase II Study,Shows Statistically Significant Impro...luated the mature phase II data from the,therapeut...that had been,obtained as part of the recently ent...e (NCI) in the US., The results from the Phase II...
    Breaking Medicine Technology:Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 5Lack of Time on Tummy Shown to Hinder Achievement of Developmental Milestones Say Physical Therapists 25084 1Lack of Time on Tummy Shown to Hinder Achievement of Developmental Milestones Say Physical Therapists 25084 2Lack of Time on Tummy Shown to Hinder Achievement of Developmental Milestones Say Physical Therapists 25084 3Lack of Time on Tummy Shown to Hinder Achievement of Developmental Milestones Say Physical Therapists 25084 4Brain Slow to Judge Fast Moving Objects Head On 25082 1Brain Slow to Judge Fast Moving Objects Head On 25082 2Autistic Children Make Limited Eye Contact 25080 1Autistic Children Make Limited Eye Contact 25080 2Autistic Children Make Limited Eye Contact 25080 3AUDIO from Medialink and BP 3A Younger for Longer 25078 1
    ...007 - CeNeS Pharmaceuticals (AIM:CEN),("CeNeS" or ...al,company today announced that a paper published ...othesis that a,catechol-O-methyltransferase (COMT)...l agent to address profound cognitive,deficits in ...ngoing discovery programme to develop novel COMT i...
    ...at Eight Weeks Sustained up to 12 Weeks,and Drug R... Calif., July 02, 2007,/PRNewswire-FirstCall/ -- A...rm, follow-up results from a Phase 2 study showing...5) in patients with,moderate-to-severe osteoarthri... pain that persisted for up to 12 weeks. , "The po...
    Other Medicine Technology:Major New Review Supports the Broader Potential of CeNeS COMT,Inhibitor Discovery Programme 2Major New Review Supports the Broader Potential of CeNeS COMT,Inhibitor Discovery Programme 3Major New Review Supports the Broader Potential of CeNeS COMT,Inhibitor Discovery Programme 4Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee 2Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee 3Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee 4Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee 5